HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SKB BIO-B

343.800

+11.0003.31%

Volume:63.76K

Turnover:22.23M

Market Cap:78.04B

PE:-265.80

High:360.000

Open:332.800

Low:328.600

Close:332.800

Loading ...

Overview Company News Filings

Kelun-Biotech's Trop2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing in Second Indication by Nmpa for Egfrm Nsclc

THOMSON REUTERS

Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing for Second Indication by Nmpa

THOMSON REUTERS

HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody

MT Newswires Live

Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy

MT Newswires Live

SKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology Meeting

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Says Cetuximab N01 Injection Approved For Marketing By NMPA China

SKB Biopharma Gets China Nod for Marketing of Cancer Drug

MT Newswires Live

Sichuan Kelun-Biotech Biopharmaceutical - Cetuximab N01 Injection Approved for Marketing by Nmpa China

THOMSON REUTERS

SKB Biopharmaceutical to Continue Leasing Property, Equipment from Controlling Shareholder

MT Newswires Live

Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc

THOMSON REUTERS

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit From CITIC Bank

Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe for Structured Deposit From CITIC Bank in Principal Amount of RMB50 Mln

THOMSON REUTERS

SKB Biopharmaceutical Gets Marketing Nod for Anti-Tumor Drug in China

MT Newswires Live

Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Drug Approval For SKB445 By NMPA China

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA

Sichuan Kelun-Biotech Biopharmaceutical - Got Drug Approval for Skb445 by Nmpa China

THOMSON REUTERS

HBM, SKB Biopharma Sign License Agreement for Anti-Asthma, COPD Drug

MT Newswires Live

Kelun-Biotech Announce Exclusive License Agreement for Skb378/Hbm9378, an Anti-Thymic Stromal Lymphopoietin (Tslp) Monoclonal Antibody (Mab).

THOMSON REUTERS

BRIEF-HBM Holdings Announces License Agreement With Windward Bio AG

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06990/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":343.8,"timestamp":1746173305036,"preClose":332.8,"halted":0,"volume":63760,"delay":0,"floatShares":157000000,"shares":227000000,"eps":-1.29346774512524,"marketStatus":"Market Closed","change":11,"latestTime":"05-02 16:08:25","open":332.8,"high":360,"low":328.6,"amount":22230168,"amplitude":0.094351,"askPrice":343.8,"askSize":1600,"bidPrice":343,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-1.29346774512524,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":332.8,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.08178164965257703,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":157000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.293468,"volumeRatio":0.08178164965257703,"shares":227000000,"dividePrice":0,"high":360,"amplitude":0.094351,"preClose":332.8,"low":328.6,"week52Low":120.2,"pbRate":"21.95","psRate":"37.57","week52High":360,"institutionHeld":0,"latestPrice":343.8,"committee":-0.391304,"eps":-1.29346774512524,"divideRate":0,"volume":63760,"delay":0,"ttmEps":-1.29346774512524,"open":332.8,"prevYearClose":163.3,"prevWeekClose":293.8,"prevMonthClose":332.8,"prevQuarterClose":290.8,"fiveDayClose":308.2,"twentyDayClose":290.8,"sixtyDayClose":159.3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518234249","title":"Kelun-Biotech's Trop2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing in Second Indication by Nmpa for Egfrm Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2518234249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518234249?lang=en_us&edition=fundamental","pubTime":"2025-03-10 18:44","pubTimestamp":1741603463,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PS05H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2518821317","title":"Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing for Second Indication by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2518821317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518821317?lang=en_us&edition=fundamental","pubTime":"2025-03-10 16:45","pubTimestamp":1741596318,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PR0D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2517185660","title":"HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185660?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:40","pubTimestamp":1741243252,"startTime":"0","endTime":"0","summary":"HBM Holdings  received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.The company and Sichuan Kelun-Biotech Biopharmaceutical  had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","02142","LU0196878994.USD","BK1161","BK1583","06990"],"gpt_icon":0},{"id":"2512600139","title":"Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2512600139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512600139?lang=en_us&edition=fundamental","pubTime":"2025-02-18 17:00","pubTimestamp":1739869228,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has an average rating of buy and price targets ranging from HK$187.10 to HK$240, according to analysts polled by Capital IQ.(MT Newswires covers equi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","NMR"],"gpt_icon":0},{"id":"2510805909","title":"SKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2510805909","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510805909?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:00","pubTimestamp":1739268009,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  will present the results of its phase 1/2 study of its sacituzumab tirumotecan drug during a meeting of the American Society of Clinical Oncology in San Francisco from Thursday to Saturday.The drug is indicated for patients with locally advanced or metastatic urothelial carcinoma who have shown progress on or after prior anti-cancer treatments, according to a Tuesday filing with the Hong Kong exchange.The drug has previous indications for advanced solid tumors such as non-small cell lung cancer, breast cancer, gastric cancer, and gynecological tumors, among others, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2509721351","title":"BRIEF-Sichuan Kelun-Biotech Says Cetuximab N01 Injection Approved For Marketing By NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2509721351","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509721351?lang=en_us&edition=fundamental","pubTime":"2025-02-08 01:23","pubTimestamp":1738949020,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Says Cetuximab N01 Injection Approved For Marketing By NMPA ChinaFeb 7 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:CETUXIMAB N01 INJECTION APPROVED FOR MARKETING BY NMPA CHINAFurther company coverage: 6990.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY10H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2509139297","title":"SKB Biopharma Gets China Nod for Marketing of Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2509139297","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509139297?lang=en_us&edition=fundamental","pubTime":"2025-02-07 18:21","pubTimestamp":1738923676,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  obtained marketing authorization for its Cetuximab N01 injection from China's National Medical Products Administration, a Friday bourse filing said.The drug is used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of rat sarcoma virus wild-type metastatic colorectal cancer, according to the biopharmaceutical company.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2509794435","title":"Sichuan Kelun-Biotech Biopharmaceutical - Cetuximab N01 Injection Approved for Marketing by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2509794435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509794435?lang=en_us&edition=fundamental","pubTime":"2025-02-07 17:00","pubTimestamp":1738918859,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY10H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2508116085","title":"SKB Biopharmaceutical to Continue Leasing Property, Equipment from Controlling Shareholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2508116085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508116085?lang=en_us&edition=fundamental","pubTime":"2025-02-03 18:51","pubTimestamp":1738579880,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  has renewed two agreements to continue leasing certain property and assets from controlling shareholder Kelun Pharmaceutical for the three years ending Dec. 31, 2027, a Jan. 28 bourse filing said.The leased properties in Chengdu, China, are being used by the company for its daily operations, such as for R&D activities, and as a storage house, office space, and staff housing solution.The equipment comprises around 1,074 pieces of equipment including manufacturing and laboratory equipment and instruments.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6520","NEX.SI","BK6039","LU0196878994.USD","CFA.SI","BK1161","06990"],"gpt_icon":0},{"id":"2505405868","title":"Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc","url":"https://stock-news.laohu8.com/highlight/detail?id=2505405868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505405868?lang=en_us&edition=fundamental","pubTime":"2025-01-23 13:27","pubTimestamp":1737610044,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA8YZ3Q0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2505614753","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit From CITIC Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2505614753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505614753?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:30","pubTimestamp":1737509438,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit From CITIC BankJan 22  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:TO SUBSCRIBE FOR STRUCTURED DEPOSIT FROM CITIC BANK IN PRINCIPAL AMOUNT OF RMB50 MILLIONFurther company coverage: 6990.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH1VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2505739155","title":"Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe for Structured Deposit From CITIC Bank in Principal Amount of RMB50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2505739155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505739155?lang=en_us&edition=fundamental","pubTime":"2025-01-22 07:29","pubTimestamp":1737502169,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH1VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2505213955","title":"SKB Biopharmaceutical Gets Marketing Nod for Anti-Tumor Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2505213955","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505213955?lang=en_us&edition=fundamental","pubTime":"2025-01-21 14:50","pubTimestamp":1737442217,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  received marketing authorization for tagitanlimab from China's National Medical Products Administration, a Monday bourse filing by the biopharmaceutical firm said.The authorization allows the use of the drug in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2505627362","title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505627362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505627362?lang=en_us&edition=fundamental","pubTime":"2025-01-21 10:39","pubTimestamp":1737427147,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.SKB445, a new antibody-drug conjugate  drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.The pharmaceutical company's shares were up by 1% in recent trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","LU0196878994.USD","BK1161","ADC.AU","BK4231","BK7095","ADC","06990"],"gpt_icon":0},{"id":"2504284648","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Drug Approval For SKB445 By NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2504284648","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504284648?lang=en_us&edition=fundamental","pubTime":"2025-01-20 23:34","pubTimestamp":1737387267,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Drug Approval For SKB445 By NMPA ChinaJan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:GOT DRUG APPROVAL FOR SKB445 BY NMPA CHINAFurther company coverage: 6990.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nFWN3OG0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2504284876","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2504284876","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504284876?lang=en_us&edition=fundamental","pubTime":"2025-01-20 23:28","pubTimestamp":1737386939,"startTime":"0","endTime":"0","summary":"Jan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2504091054","title":"Sichuan Kelun-Biotech Biopharmaceutical - Got Drug Approval for Skb445 by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2504091054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504091054?lang=en_us&edition=fundamental","pubTime":"2025-01-20 19:59","pubTimestamp":1737374366,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nFWN3OG0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2503373805","title":"HBM, SKB Biopharma Sign License Agreement for Anti-Asthma, COPD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503373805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503373805?lang=en_us&edition=fundamental","pubTime":"2025-01-13 17:20","pubTimestamp":1736760050,"startTime":"0","endTime":"0","summary":"HBM Holdings  and Sichuan Kelun-Biotech Biopharmaceutical  signed a license agreement with Windward Bio for their joint anti-thymic stromal lymphopoietin monoclonal antibody , according to a Friday filing with the Hong Kong exchange.The drug, coded SKB378/HBM9378, is an antibody that blocks receptors responsible for immunological conditions such as asthma and chronic obstructive pulmonary disease or COPD, the filing said.Under the agreement, Switzerland-based Windward Bio will gain an exclusive license for the research, development, manufacturing and commercialization of the drug across the globe, except in Greater China and several Southeast and West Asian countries, the filing said.Both HBM and SKB are set to gain $970 million in upfront and milestone payments and single to double-digit tiered royalties on net sales of the drug, the filing said.The $45 million in upfront and near-term payments include cash and equity in Windward Bio's parent, the filing said.Both HBM and SKB will als","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","02142","06990","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2502135876","title":"Kelun-Biotech Announce Exclusive License Agreement for Skb378/Hbm9378, an Anti-Thymic Stromal Lymphopoietin (Tslp) Monoclonal Antibody (Mab).","url":"https://stock-news.laohu8.com/highlight/detail?id=2502135876","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502135876?lang=en_us&edition=fundamental","pubTime":"2025-01-11 16:37","pubTimestamp":1736584652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250111:nTUAB61RRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2502289301","title":"BRIEF-HBM Holdings Announces License Agreement With Windward Bio AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2502289301","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502289301?lang=en_us&edition=fundamental","pubTime":"2025-01-10 23:43","pubTimestamp":1736523789,"startTime":"0","endTime":"0","summary":"Jan 10  - Hbm Holdings Ltd   :   * ENTERING INTO LICENSE AGREEMENT WITH WINDWARD BIO AG   * LICENSE AGREEMENT TO GRANT WINDWARD BIO AN EXCLUSIVE WORLDWIDE LICENSE TO MANUFACTURE, AMONG OTHERS, HBM9378/SKB378   * LICENSE AGREEMENT EXCLUDES GREATER CHINA AND SEVERAL SOUTHEAST AND WEST ASIAN COUNTRIESFurther company coverage:    ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","LU0196878994.USD","06990","BK1583","BK1161","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post Market","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"Post Market","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744732800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-05-02","current":-274.570331,"percent":0,"low":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"high":-21.029201,"avg":-100.2239,"sd":64.780777,"marketCap":78134738400},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400}],"updateTime":1746263241835}}}